Hospira Inc., of Lake Forest, Ill., received FDA approval for Dyloject (diclofenac sodium) Injection, a nonsteroidal anti-inflammatory drug analgesic. Read More
Can-Fite Biopharma Ltd., of Petach Tikva, Israel, completed the design of a rheumatoid arthritis (RA) phase III study of its lead drug candidate CF101. Read More
Oncogenex Pharmaceuticals Inc., of Bothell, Wash., executed an initial agreement with Teva Pharmaceutical Industries Ltd., of Jerusalem, to regain rights to custirsen, an investigational compound being evaluated in phase III development as a treatment for prostate and lung cancers. Read More
Kite Pharma Inc., of Santa Monica, Calif., said the underwriters of its follow-on public offering of 3.485 million shares of common stock have exercised in full their option to purchase an additional 522,750 shares of common stock at the public offering price of $54 per share. Read More
HONG KONG – The health care industry in China could go through a period of flux over the next year as it responds to widespread changes to the country's economy. Read More
LONDON – T helper cells, which help to coordinate the immune response, do recognize mutations found in cancer cells, researchers have found. The discovery suggests that it may one day be possible to use T helper cells in cancer immunotherapy, by stimulating them to recognize specific tumors. Read More
SHANGHAI – China's chief economic planning agency has proposed changes to the way medicine prices are set that will allow more room for market forces and do away with government set price caps. Released in a draft discussion document last month, the new policy is expected to come into force Jan. 1, 2015. Read More
With another warm reception predicted for biopharma IPOs in 2015, three more companies are looking to take advantage and enter the public arena. San Diego-based Tracon Pharmaceuticals Inc. is developing chimeric antibodies for cancer and age-related macular degeneration therapies and has filed to raise $58 million from its offering. Read More
With favorable results in hand from a phase IIa pharmacokinetic (PK) study with its Parkinson's disease (PD) treatments, Neuroderm Ltd. is planning a head-to-head trial against Abbvie Inc.'s Duodopa – cleared in Europe, pending in the U.S. – next year, Oded Lieberman, CEO of the Rehovot, Israel-based firm, told BioWorld Today Read More
